



PHARMACEUTICAL 2023












RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of RAPT Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RAPT Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of RAPT Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 235%, being 192% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	252,694
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,224
Liabilities, Non-Current	6,819
Other Assets	10,976
Other Compr. Net Income	180
Other Expenses	0
Other Liabilities	0
Other Net Income	1,957
Other Revenues	1,527
Property and Equipment	2,539
Research and Development	67,082
Selling, General and Administrative Expense	20,240

Output Variable	Value in 1000 USD
Assets	266,209
Liabilities	21,043
Expenses	87,322
Revenues	1,527
Stockholders Equity	245,166
Net Income	-83,838
Comprehensive Net Income	-83,748
Economic Capital Ratio	235%

